 SAN DIEGO and CALGARY, Alberta , June 25, 2020 CNW -- Oncolytics Biotech Inc. ONCY ONC.TO, today announced a new investigator-sponsored triple-negative breast cancer TNBC study to be managed by Rutgers Cancer Institute of New Jersey . The phase 2 trial, known as IRENE, will investigate the use of pelareorep in combination with Incytes anti-PD-1 checkpoint inhibitor retifanlimab INCMGA00012 in patients with unresectable locally advanced or metastatic TNBC. We are very excited to evaluate pelareorep in TNBC, as prior clinical data show it has the potential to address a pressing unmet need in this challenging indication, said principal investigator Mridula George , M.D., Medical Oncologist, Rutgers Cancer Institute of New Jersey and Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School. 